by Mark Chiang

马克·蒋

Share To

分享到

Sagent Pharmaceuticals has entered into a partnership with Qilu Pharmaceutical to commercialize a portfolio of complex injectable products in the United States. Under the agreement, Sagent will hold exclusive rights to market and distribute select products developed by Qilu, which target high-impact therapeutic areas..

Sagent制药公司与齐鲁制药达成合作，将在美国市场商业化推广一系列复杂的注射产品。根据协议，Sagent将拥有独家权利，营销和分销由齐鲁开发的针对高影响力治疗领域的产品。

The collaboration focuses on expanding access to advanced injectable treatments within the U.S. healthcare market. The specific details regarding the product portfolio or therapeutic categories were not disclosed, but both companies aim to leverage their combined expertise in pharmaceutical development and commercialization..

该合作的重点是扩大美国医疗市场中先进注射治疗的可及性。虽然尚未披露有关产品组合或治疗类别的具体细节，但双方公司都希望利用其在药物研发和商业化方面的综合专业知识。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: Got it! Please provide the date you’d like me to format, and I’ll convert it for you.

日期：明白了！请提供您想要格式化的日期，我会为您转换。

Related posts:

相关内容：

European Biosimilar Market to Reach €53.4 Billion by 2025, Fueling Generics Growth

欧洲生物仿制药市场到2025年将达到534亿欧元，推动仿制药增长

Study Reveals Ventral Tegmental Area Encodes Timing of Expected Rewards Alongside Value

研究揭示腹侧被盖区编码预期奖励的时间和价值

High-Fiber Plant-Based Diet Linked to Delayed Progression of Precancerous Conditions in Multiple Myeloma Risk Study

高纤维植物性饮食与多发性骨髓瘤风险研究中癌前病变进展延迟相关

FDA Approves Low-IgA Immunoglobulin Formulation for Primary Immunodeficiency Patients

FDA批准低IgA免疫球蛋白制剂用于原发性免疫缺陷患者

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·蒋

Related Post

相关帖子

News Flash

新闻快讯

Moderna’s mRNA-1010 Flu Vaccine Meets Primary Endpoint in Older Adults Clinical Trial

Moderna的mRNA-1010流感疫苗在老年人临床试验中达到主要终点

2025-07-11

2025年7月11日